Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase ...
"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...
Developers have a growing array of options for AI-powered low-code and no-code development tools. But using them to their ...
Their shared dedication reflects a broader mission to bring meaningful change to women’s health, offering hope and tangible ...
Havco Wood Products, Major Custom Cable and Alan Wire show how data, selective automation and relentless training are ...
With rate cuts expected in 2026, bonds are likely to outperform cash, according to PGIM. The firm’s 2026 outlook highlights ...
FOSHAN, GUANGDONG, CHINA, January 12, 2026 /EINPresswire.com/ -- Foshan AoChuanShun New Material Industrial Co., Ltd.
7hon MSN
Evaluating apps for treating depression: Study finds most aren't supported by scientific evidence
Diagnoses of depression, one of the most common mental disorders, increased by nearly 50% between 1990 and 2017, according to ...
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus ...
The Company is scheduled to participate in a fireside chat presentation on Monday, January 12, 2026, at 9:30 a.m. Eastern Time at the ICR conference. This event will be webcast live and a replay will ...
The annual Consumer Electronics Show (CES for short) is the place to be right now if you’re in tech, and the new pet tech ...
Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback